-
Something wrong with this record ?
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial
M. Kuhlen, AM. Willasch, JH. Dalle, J. Wachowiak, I. Yaniv, M. Ifversen, P. Sedlacek, T. Guengoer, P. Lang, P. Bader, S. Sufliarska, A. Balduzzi, B. Strahm, I. von Luettichau, JI. Hoell, A. Borkhardt, T. Klingebiel, M. Schrappe, A. von...
Language English Country Great Britain
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
29193007
DOI
10.1111/bjh.14965
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis mortality therapy MeSH
- Survival Analysis MeSH
- Time Factors MeSH
- Child MeSH
- Transplantation, Homologous MeSH
- Remission Induction MeSH
- Infant MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Retreatment MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Proportional Hazards Models MeSH
- Recurrence MeSH
- Hematopoietic Stem Cell Transplantation adverse effects methods MeSH
- Treatment Outcome MeSH
- Salvage Therapy MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
Relapse remains the major cause of treatment failure in children with high-risk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk factors and outcome are lacking from prospective studies. We analysed 242 children with recurrence of ALL after first allo-SCT enrolled in the Berlin-Frankfurt-Munster (BFM) ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 studies. Median time from allo-SCT to relapse was 7·7 months; median follow-up from relapse after allo-SCT until last follow-up was 3·4 years. The 3-year event-free survival (EFS) was 15% and overall survival (OS) was 20%. The main cause of death was disease progression or relapse (86·5%). The majority of children (48%) received salvage therapy without second allo-SCT, 26% of the children underwent a second allo-SCT and 25% received palliative treatment only. In multivariate analyses, age, site of relapse, time to relapse and type of salvage therapy were identified as significant prognostic factors for OS and EFS, whereas factors associated with first SCT were not statistically significant. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapse.
Clinica Pediatrica Università degli Studi di Milano Bicocca Ospedale San Gerardo Monza Italy
Department of Paediatric Haematology and Oncology Teaching Hospital Motol Prague Czech Republic
Department of Paediatrics University Medical Centre Schleswig Holstein Kiel Germany
Division of Stem Cell Transplantation University Children's Hospital Zürich Zürich Switzerland
Paediatric Haematology Department Robert Debré Hospital and Paris Diderot University Paris France
St Anna Children's Hospital Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010259
- 003
- CZ-PrNML
- 005
- 20180404141922.0
- 007
- ta
- 008
- 180404s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.14965 $2 doi
- 035 __
- $a (PubMed)29193007
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kuhlen, Michaela $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, University Children's Hospital, Heinrich Heine University, Duesseldorf, Germany.
- 245 10
- $a Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial / $c M. Kuhlen, AM. Willasch, JH. Dalle, J. Wachowiak, I. Yaniv, M. Ifversen, P. Sedlacek, T. Guengoer, P. Lang, P. Bader, S. Sufliarska, A. Balduzzi, B. Strahm, I. von Luettichau, JI. Hoell, A. Borkhardt, T. Klingebiel, M. Schrappe, A. von Stackelberg, E. Glogova, U. Poetschger, R. Meisel, C. Peters,
- 520 9_
- $a Relapse remains the major cause of treatment failure in children with high-risk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk factors and outcome are lacking from prospective studies. We analysed 242 children with recurrence of ALL after first allo-SCT enrolled in the Berlin-Frankfurt-Munster (BFM) ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 studies. Median time from allo-SCT to relapse was 7·7 months; median follow-up from relapse after allo-SCT until last follow-up was 3·4 years. The 3-year event-free survival (EFS) was 15% and overall survival (OS) was 20%. The main cause of death was disease progression or relapse (86·5%). The majority of children (48%) received salvage therapy without second allo-SCT, 26% of the children underwent a second allo-SCT and 25% received palliative treatment only. In multivariate analyses, age, site of relapse, time to relapse and type of salvage therapy were identified as significant prognostic factors for OS and EFS, whereas factors associated with first SCT were not statistically significant. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapse.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a akutní lymfatická leukemie $x diagnóza $x mortalita $x terapie $7 D054198
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a opakovaná terapie $7 D019233
- 650 _2
- $a záchranná terapie $7 D016879
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Willasch, Andre M $u Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
- 700 1_
- $a Dalle, Jean-Hugues $u Paediatric Haematology Department, Robert Debré Hospital and Paris Diderot University, Paris, France.
- 700 1_
- $a Wachowiak, Jacek $u University of Medical Sciences, Poznan, Poland.
- 700 1_
- $a Yaniv, Isaac $u Ezer Mizion Bone Marrow Donor Registry, Petach Tikva, Israel. Bone Marrow Transplant Unit, Schneider Children's Medical Centre of Israel, Petach Tikva, Israel.
- 700 1_
- $a Ifversen, Marianne $u Department for Children and Adolescents, Rigahospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- 700 1_
- $a Sedlacek, Petr $u Department of Paediatric Haematology and Oncology, Teaching Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Guengoer, Tayfun $u Division of Stem Cell Transplantation, University Children's Hospital Zürich, Zürich, Switzerland.
- 700 1_
- $a Lang, Peter $u University Hospital Tuebingen, Tuebingen, Germany.
- 700 1_
- $a Bader, Peter $u Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
- 700 1_
- $a Sufliarska, Sabina $u Department of Paediatric Haematology and Oncology, Haematopoietic Stem Cell Transplantation Unit, Comenius University Children's Hospital Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Balduzzi, Adriana $u Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
- 700 1_
- $a Strahm, Brigitte $u Department of Paediatrics and Adolescent Medicine, Division of Paediatric Haematology and Oncology, Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- 700 1_
- $a von Luettichau, Irene $u Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. Comprehensive Cancer Centre Munich (CCCM), Munich, Germany.
- 700 1_
- $a Hoell, Jessica I $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, University Children's Hospital, Heinrich Heine University, Duesseldorf, Germany.
- 700 1_
- $a Borkhardt, Arndt $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, University Children's Hospital, Heinrich Heine University, Duesseldorf, Germany.
- 700 1_
- $a Klingebiel, Thomas $u Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
- 700 1_
- $a Schrappe, Martin $u Department of Paediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a von Stackelberg, Arend $u Department of Paediatric Oncology/Haematology, Charité Universitätsmedizin Berlin, Charité Campus Virchow, Berlin, Germany.
- 700 1_
- $a Glogova, Evgenia $u St. Anna Children's Hospital, Vienna, Austria.
- 700 1_
- $a Poetschger, Ulrike $u St. Anna Children's Hospital, Vienna, Austria.
- 700 1_
- $a Meisel, Roland $u Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, University Children's Hospital, Heinrich Heine University, Duesseldorf, Germany.
- 700 1_
- $a Peters, Christina $u St. Anna Children's Hospital, Vienna, Austria.
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 180, č. 1 (2018), s. 82-89
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29193007 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180404142002 $b ABA008
- 999 __
- $a ok $b bmc $g 1287744 $s 1007071
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 180 $c 1 $d 82-89 $e 20171128 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20180404
